Join our esteemed faculty to navigate the complexities of treating patients with newly diagnosed multiple myeloma (NDMM) in clinical practice. Explore the individualisation of treatment strategies for patients with NDMM including disease specific characteristics, real world evidence and patient eligibility and hear from the faculty their perspectives on effective disease management.

Our panellists will discuss practical treatment approaches in the fittest and frailest patients, supported by key data from relevant clinical trials in both transplant-eligible and transplant-ineligible populations. They will also cover topics such as the achievement of cure or ‘functional cure’ in the era of anti-CD38-based regimens and tailoring these regimens to maximise outcomes across diverse patient populations. Engage directly with our faculty during a dedicated Q&A session, where you can pose questions closely aligned with your clinical practice and gain personalised insights.

We eagerly anticipate your participation in this transformative symposium and look forward to welcoming you!

Click here to find out more about the two symposia hosted by Johnson & Johnson at COMy 2025.